Canada Eyes Reducing Reliance On Pricing As Sole Reward for Innovation
A New Framework For Funding Rare Disease Treatments Is Under Consideration
Up-front R&D investments from third parties in an effort to share risk and reduce industry’s reliance on pricing as the sole reward for innovation could be on the cards in Canada, as could a new single approach for deciding which drugs to cover.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.